Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$36.90 -1.0%	$40.09	$26.20 ▼ $63.50	$1.70B	1.43	745,893 shs	297,783 shs
CAPR Capricor Therapeutics	$7.70 -3.3%	$9.17	$3.94 ▼ $23.40	$352.04M	0.59	2.02 million shs	1.18 million shs
DYN Dyne Therapeutics	$12.33 -0.4%	$10.46	$6.36 ▼ $47.45	$1.75B	1.08	2.64 million shs	1.89 million shs
IMCR Immunocore	$32.31 -1.7%	$33.60	$23.15 ▼ $39.33	$1.63B	0.77	337,610 shs	193,900 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	+5.37%	-5.14%	-6.56%	-17.59%
CAPR Capricor Therapeutics	0.00%	-12.24%	+15.70%	-23.24%	+101.01%
DYN Dyne Therapeutics	0.00%	+10.93%	+37.25%	+6.17%	-72.73%
IMCR Immunocore	0.00%	+2.85%	-9.45%	+6.06%	-9.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APGE Apogee Therapeutics	2.8799 of 5 stars	3.5	3.0	1.7	4.2	0.0
CAPR Capricor Therapeutics	3.021 of 5 stars	4.6	2.0	2.1	0.8	0.6
DYN Dyne Therapeutics	3.4242 of 5 stars	4.5	1.0	1.9	5.0	0.0
IMCR Immunocore	1.9356 of 5 stars	3.3	1.0	2.8	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	3.00	Buy	$99.00	168.29% Upside
CAPR Capricor Therapeutics	3.11	Buy	$22.56	192.93% Upside
DYN Dyne Therapeutics	3.00	Buy	$33.80	174.13% Upside
IMCR Immunocore	2.50	Moderate Buy	$58.00	79.51% Upside

Current Analyst Ratings Breakdown

Latest CAPR, APGE, IMCR, and DYN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	APGE Apogee Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
8/6/2025	DYN Dyne Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $13.00
7/31/2025	DYN Dyne Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$66.00 ➝ $36.00
7/29/2025	DYN Dyne Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $23.00
7/29/2025	DYN Dyne Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$37.00 ➝ $31.00
7/29/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $38.00
7/15/2025	DYN Dyne Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.00
7/14/2025	CAPR Capricor Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/14/2025	CAPR Capricor Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$31.00 ➝ $12.00
7/11/2025	DYN Dyne Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/11/2025	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$15.92 per share	N/A
CAPR Capricor Therapeutics	$22.27M	15.81	N/A	N/A	$3.20 per share	2.41
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.19 per share	N/A
IMCR Immunocore	$310.20M	5.25	N/A	N/A	$7.20 per share	4.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$182.15M	-$4.13	N/A	N/A	N/A	N/A	-34.65%	-32.76%	N/A
CAPR Capricor Therapeutics	-$40.47M	-$1.64	N/A	N/A	N/A	-181.71%	-62.71%	-50.82%	N/A
DYN Dyne Therapeutics	-$317.42M	-$3.86	N/A	N/A	N/A	N/A	-64.12%	-56.75%	N/A
IMCR Immunocore	-$51.09M	-$0.40	N/A	N/A	N/A	-5.70%	-5.40%	-1.93%	11/5/2025 (Estimated)

Latest CAPR, APGE, IMCR, and DYN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	APGE Apogee Therapeutics	-$1.03	-$1.13	-$0.10	-$1.13	N/A	N/A
8/11/2025	Q2 2025	CAPR Capricor Therapeutics	-$0.48	-$0.57	-$0.09	-$0.57	$2.60 million	N/A
8/7/2025	Q2 2025	IMCR Immunocore	-$0.21	-$0.20	+$0.01	-$0.20	$122.96 million	$130.65 million
7/28/2025	Q2 2025	DYN Dyne Therapeutics	-$0.99	-$0.97	+$0.02	-$0.97	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	16.36	16.36
CAPR Capricor Therapeutics	N/A	4.37	4.37
DYN Dyne Therapeutics	0.17	16.83	16.83
IMCR Immunocore	1.01	5.89	5.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
CAPR Capricor Therapeutics	21.68%
DYN Dyne Therapeutics	96.68%
IMCR Immunocore	84.50%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	42.77%
CAPR Capricor Therapeutics	10.50%
DYN Dyne Therapeutics	20.77%
IMCR Immunocore	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	46.11 million	26.39 million	Optionable
CAPR Capricor Therapeutics	101	45.72 million	40.92 million	Optionable
DYN Dyne Therapeutics	100	142.26 million	112.72 million	Optionable
IMCR Immunocore	320	50.39 million	45.15 million	Optionable

CAPR, APGE, IMCR, and DYN Headlines

Recent News About These Companies

Q3 Earnings Forecast for Immunocore Issued By HC Wainwright

August 16 at 8:47 AM | marketbeat.com

What is HC Wainwright's Estimate for Immunocore Q3 Earnings?

August 16 at 2:47 AM | americanbankingnews.com

Immunocore FY2027 EPS Forecast Increased by HC Wainwright

August 15 at 9:59 AM | marketbeat.com

FY2027 EPS Estimates for Immunocore Boosted by HC Wainwright

August 14, 2025 | americanbankingnews.com

Persistent Asset Partners Ltd Purchases New Stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR)

August 13, 2025 | marketbeat.com

Immunocore’s Earnings Call Highlights Robust Growth and Strategic Expansion

August 13, 2025 | msn.com

Immunocore Holdings plc (NASDAQ:IMCR) Q2 2025 Earnings Call Transcript

August 13, 2025 | msn.com

Immunocore (NASDAQ:IMCR) Cut to Hold at Wall Street Zen

August 10, 2025 | marketbeat.com

Immunocore Holdings plc (IMCR) Q2 2025 Earnings Call Transcript

August 9, 2025 | seekingalpha.com

Immunocore Holdings plc 2025 Q2 - Results - Earnings Call Presentation

August 9, 2025 | seekingalpha.com

Immunocore Holdings PLC (IMCR) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...

August 8, 2025 | finance.yahoo.com

Immunocore (IMCR) Q2 Revenue Jumps 30%

August 8, 2025 | aol.comA

Primecap Management Co. CA Increases Position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR)

August 8, 2025 | marketbeat.com

Compared to Estimates, Immunocore (IMCR) Q2 Earnings: A Look at Key Metrics

August 7, 2025 | zacks.com

Immunocore reports second quarter financial results and provides a business update

August 7, 2025 | globenewswire.com

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Shares Sold by BIT Capital GmbH

August 4, 2025 | marketbeat.com

TD Asset Management Inc Reduces Position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR)

August 2, 2025 | marketbeat.com

Immunocore (IMCR) Expected to Announce Quarterly Earnings on Thursday

August 1, 2025 | marketbeat.com

Immunocore to report second quarter 2025 financial results and host call on August 7, 2025

July 31, 2025 | globenewswire.com

Fiera Capital Corp Boosts Stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR)

July 30, 2025 | marketbeat.com

Wall Street Analysts See a 72.34% Upside in Immunocore (IMCR): Can the Stock Really Move This High?

July 24, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR, APGE, IMCR, and DYN Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$36.90 -0.39 (-1.05%)

Closing price 04:00 PM Eastern

Extended Trading

$36.90 0.00 (0.00%)

As of 04:10 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Capricor Therapeutics NASDAQ:CAPR

$7.70 -0.26 (-3.27%)

Closing price 04:00 PM Eastern

Extended Trading

$7.77 +0.07 (+0.91%)

As of 04:36 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Dyne Therapeutics NASDAQ:DYN

$12.33 -0.05 (-0.40%)

Closing price 04:00 PM Eastern

Extended Trading

$12.34 +0.01 (+0.04%)

As of 04:41 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Immunocore NASDAQ:IMCR

$32.31 -0.57 (-1.73%)

Closing price 04:00 PM Eastern

Extended Trading

$32.42 +0.10 (+0.32%)

As of 04:10 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time